Search Result

Isoforms Recommended:	Akt1 Akt1

Results for "

AKT-1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (123) AMPK (9) Apoptosis (34) Autophagy (15) Bacterial (5) Bcl-2 Family (8) Bcr-Abl (1) c-Met/HGFR (2) c-Myc (1) CaMK (2) Casein Kinase (1) Caspase (11) CDK (4) COX (1) DGK (1) DNA-PK (3) DNA/RNA Synthesis (1) Drug Isomer (1) EGFR (5) Elastase (1) Endogenous Metabolite (1) Environmental Pollutants (1) Epigenetic Reader Domain (2) ERK (3) Estrogen Receptor/ERR (2) FAK (2) FOXO (2) Fungal (2) FXR (1) GSK-3 (5) HDAC (1) Histone Methyltransferase (1) HPV (1) HSP (3) HSV (2) Influenza Virus (1) Insulin Receptor (1) Interleukin Related (2) Isotope-Labeled Compounds (1) JNK (2) Keap1-Nrf2 (1) Ligands for E3 Ligase (1) MDM-2/p53 (7) MELK (1) Microtubule/Tubulin (2) Mitochondrial Metabolism (2) Mitophagy (1) MMP (3) mTOR (8) NF-κB (1) NO Synthase (2) Organoid (5) Oxidative Phosphorylation (1) p38 MAPK (3) Parasite (3) PARP (3) PDGFR (1) PDK-1 (4) PERK (2) PGC-1α (1) Phosphatase (1) PI3K (5) PKA (6) PKC (4) PPAR (2) Prostaglandin Receptor (1) PROTAC Linkers (1) PROTACs (7) PTEN (2) Ras (1) Reactive Oxygen Species (ROS) (6) Reference Standards (14) Ribosomal S6 Kinase (RSK) (9) ROCK (5) Ser/Thr Protease (2) SGK (2) Small Interfering RNA (siRNA) (4) SOD (1) SphK (1) Src (2) STAT (4) Survivin (1) Toll-like Receptor (TLR) (1) Trk Receptor (1) VEGFR (3)
By Research Areas:	Cancer (115) Cardiovascular Disease (6) Endocrinology (5) Infection (14) Inflammation/Immunology (17) Metabolic Disease (15) Neurological Disease (9)
Click Chemistry:	PROTAC Synthesis (1) Alkynes (1)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (2) Antisense Oligonucleotides (2) siRNAs (4)

139

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Capivasertib 80+ Cited Publications AZD5363	Akt Autophagy	Cancer
Capivasertib (AZD5363) is an orally active and potent *pan-AKT* kinase inhibitor with IC₅₀ of 3, 7 and 7 nM for *Akt1,Akt2* and *Akt3*, respectively.

Oridonin Maximum Cited Publications 26 Publications Verification NSC-250682; Isodonol	Akt Bacterial Ligands for E3 Ligase	Infection Inflammation/Immunology Cancer
Oridonin (NSC-250682), a diterpenoid isolated from Rabdosia rubescens, acts as an inhibitor of *AKT, with IC₅₀s of 8.4 and 8.9 μM for AKT1* and AKT2; Oridonin possesses anti-tumor, anti-bacterial and anti-inflammatory effects.

Ipatasertib 55+ Cited Publications GDC-0068; RG7440	Organoid Akt Apoptosis	Cancer
Ipatasertib (GDC-0068) is an orally active, highly selective and ATP-competitive pan-Akt inhibitor with IC₅₀ values of 5, 18, 8 nM for *Akt1/2/3, respectively. Ipatasertib synchronously activates FoxO3a and NF-κB through inhibition of Akt* leading to p53-independent activation of PUMA. Ipatasertib also induces apoptosis in cancer cells and inhibits tumor growth in xenograft mouse models ^[1] .

AKT inhibitor VIII 55+ Cited Publications AKTi-1/2	Akt Apoptosis	Metabolic Disease Cancer
AKT inhibitor VIII (AKTi-1/2) is a cell-permeable quinoxaline compound that has been shown to potently, selectively, allosterically, and reversibly inhibit *Akt1, Akt2, and Akt3* activity with IC₅₀s of 58 nM, 210 nM, and 2119 nM, respectively.

Uprosertib 15+ Cited Publications GSK2141795	Akt	Cancer
Uprosertib (GSK2141795) is a potent and selective *pan-Akt* inhibitor with IC₅₀ values of 180/328/38 nM for Akt1/Akt2/Akt3, respectively.

Afuresertib 15+ Cited Publications GSK2110183; LAE002	Akt PKC ROCK	Cancer
Afuresertib (GSK2110183) is an orally bioavailable, selective, ATP-competitive and potent pan-Akt kinase inhibitor with K_is of 0.08/2/2.6 nM for Akt1/Akt2/Akt3, respectively ^[1] .

BAY1125976 3 Publications Verification	Akt	Cancer
BAY1125976, a chemical probe, is a selective allosteric *Akt1/Akt2* inhibitor; inhibits Akt1 and Akt2 activity with IC₅₀ values of 5.2 nM and 18 nM at 10 μM ATP, respectively.

Miransertib 15+ Cited Publications ARQ-092	Akt Parasite	Infection Cancer
Miransertib (ARQ-092) is a potent, orally active, selective and allosteric *Akt* inhibitor with IC₅₀s of 2.7 nM, 14 nM and 8.1 nM for *Akt1, Akt2, Akt3, respectively. Miransertib is also a potent the AKT1-E17K* mutant protein inhibitor and has the potential for PI3K/AKT-driven tumors and Proteus syndrome research ^[1]. Miransertib is effective against *Leishmania* .

GSK-690693 40+ Cited Publications	Akt AMPK Autophagy	Cancer
GSK-690693 is an ATP-competitive *pan-Akt* inhibitor with IC₅₀s of 2 nM, 13 nM, 9 nM for *Akt1, Akt2* and *Akt3, respectively. GSK-690693 is also an AMPK* inhibitor, affects Unc-51-like autophagy activating kinase 1 (ULK1) activity and robustly inhibits STING-dependent IRF3 activation ^[1] .

INY-03-041 1 Publications Verification	PROTACs Akt	Cancer
INY-03-041 is a potent, highly selective and PROTAC-based pan-AKT degrader consisting of the ATP-competitive *AKT* inhibitor Ipatasertib (HY-15186) conjugated to Lenalidomide (HY-A0003, Cereblon ligand). INY-03-041 inhibits *AKT1, AKT2* and *AKT3* with IC₅₀s of 2.0, 6.8 and 3.5 nM, respectively ^[1].

AT13148 2 Publications Verification	Akt PKA ROCK Ribosomal S6 Kinase (RSK)	Cancer
AT13148 is an orally active and ATP-competitive, multi-AGC kinase inhibitor with IC₅₀s of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively.

Tanerasertib	Akt	Cancer
Tanerasertib (Compound 456) is an *AKT1* inhibitor, targerting to AKT1 ^E17K with the EC₅₀ of 15-60 nM. Tanerasertib can be used in the study of cancer ^[1].

Rizavasertib 10+ Cited Publications A-443654	Akt	Cancer
A-443654 is a *pan-Akt* inhibitor and has equal potency against *Akt1, Akt2, or Akt3* within cells (K_i=160 pM) ^[1].

A-674563 hydrochloride 5 Publications Verification	Akt	Cancer
A-674563 hydrochloride is a potent and selective *Akt1* inhibitor with K_i of 11 nM.

CaMKII-IN-1 5 Publications Verification	CaMK	Neurological Disease
CaMKII-IN-1 is a highly selective inhibitor of CaMKII with an IC50 value of 63nM. It has almost no effect on CaMKIV, MLCK, p38a, Akt1, and PKC.

Engasertib 2 Publications Verification ALM301	Akt	Cancer
Engasertib is an orally active highly specific *AKT* inhibitor with IC₅₀ values of 0.13 µM, 0.09 µM and 2.75 µM for AKT1, AKT2 and AKT3, respectively. Engasertib inhibits AKT phosphorylation and modulates downstream signalling in vitro. Engasertib can inhibit cancer cell proliferation and tumor growth ^[1].

M2698 1 Publications Verification MSC2363318A	Ribosomal S6 Kinase (RSK) Akt	Cancer
M2698 (MSC2363318A) is an orally active, ATP competitive, selective p70S6K and *Akt* dual-inhibitor with IC₅₀s of 1 nM for p70S6K, Akt1 and Akt3. M2698 can cross the blood-brain barrier and has anti-cancer activity ^[1].

Pifusertib TAS-117	Akt Apoptosis Autophagy	Cancer
Pifusertib (TAS-117) is a potent, selective, orally active allosteric *Akt* inhibitor (with IC₅₀s of 4.8, 1.6, and 44 nM for Akt1, 2, and 3, respectively). Pifusertib triggers anti-myeloma activities and enhances fatal endoplasmic reticulum (ER) stress induced by proteasome inhibition. Pifusertib induces apoptosis and autophagy ^[1].

Triadimefon	Environmental Pollutants AMPK Akt PERK Fungal	Infection Neurological Disease Metabolic Disease Endocrinology
Triadimefon is an orally active fungicide. Triadimefon significantly reduces the phosphorylation of *AKT1* and *ERK1/2. Triadimefon significantly increases pAMPK* levels, but does not affect total AMPK levels. Triadimefon inhibits the growth of Saccharomyces cerevisiae, disrupts hormone homeostasis (affecting the synthesis of testosterone, etc.), inhibits fetal adrenal development in rats, induces metabolic shifts in hepatocytes, and impairs spatial learning and memory ^[1] .

Vevorisertib trihydrochloride 1 Publications Verification ARQ 751 trihydrochloride	Akt	Cancer
Vevorisertib (ARQ 751) trihydrochloride is a selective, allosteric, pan-AKT and AKT1-E17K mutant inhibitors. Vevorisertib trihydrochloride potently inhibit phosphorylation of AKT. Vevorisertib trihydrochloride has Kd values of 1.2 nM and 8.6 nM for AKT1 and AKT1-E17K, respectively. Vevorisertib trihydrochloride has IC₅₀ values of 0.55, 0.81, and 1.3 nM for AKT1, AKT2, and AKT3, respectively. Vevorisertib trihydrochloride can be used for the research of cancer ^[1].

A-674563 5 Publications Verification	Akt	Cancer
A-674563 is an orally active *Akt1* inhibitor with a K_i of 11 nM.

Miransertib hydrochloride 15+ Cited Publications ARQ-092 hydrochloride	Akt Parasite	Infection Cancer
Miransertib hydrochloride (ARQ-092 hydrochloride) is a potent, orally active, selective and allosteric *Akt* inhibitor with IC₅₀s of 2.7 nM, 14 nM and 8.1 nM for *Akt1, Akt2, Akt3, respectively. Miransertib hydrochloride is also a potent the AKT1-E17K* mutant protein inhibitor and has the potential for PI3K/AKT-driven tumors and Proteus syndrome research ^[1]. Miransertib hydrochloride is effective against *Leishmania* .

Afuresertib hydrochloride 15+ Cited Publications GSK2110183 hydrochloride; LAE002 hydrochloride	Akt PKC ROCK	Cancer
Afuresertib hydrochloride (GSK 2110183 hydrochloride) is an orally bioavailable, selective, ATP-competitive and potent pan-Akt kinase inhibitor with K_is of 0.08/2/2.6 nM for Akt1/Akt2/Akt3 respectively ^[1] .

Ipatasertib dihydrochloride 55+ Cited Publications GDC-0068 dihydrochloride; RG-7440 dihydrochloride	Organoid Akt	Cancer
Ipatasertib dihydrochloride (GDC-0068 dihydrochloride) is a highly selective and ATP-competitive *pan-Akt* inhibitor with IC₅₀s of 5, 18 and 8 nM for *Akt1, Akt2* and *Akt3*, respectively.

AT7867 5 Publications Verification	Akt PKA Ribosomal S6 Kinase (RSK)	Cancer
AT7867 is a potent ATP-competitive inhibitor of *Akt1/Akt2/Akt3* and p70S6K/PKA with IC₅₀s of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively.

Hu7691	Akt PKA PKC ROCK Ribosomal S6 Kinase (RSK) SGK	Cancer
Hu7691 is an orally active, selective *Akt* inhibitor with IC₅₀s of 4.0 nM, 97.5 nM, 28 nM for Akt1, Akt2 and Akt3, respectively. Hu7691 inhibits tumor growth and enables decrease of cutaneous toxicity in mice ^[1].

Pifusertib hydrochloride TAS-117 hydrochloride	Akt Apoptosis Autophagy	Cancer
Pifusertib (TAS-117) hydrochloride is a potent, selective, orally active allosteric *Akt* inhibitor (with IC₅₀s of 4.8, 1.6, and 44 nM for Akt1, 2, and 3, respectively). Pifusertib hydrochloride triggers anti-myeloma activities and enhances fatal endoplasmic reticulum (ER) stress induced by proteasome inhibition. Pifusertib hydrochloride induces apoptosis and autophagy ^[1].

SETDB1-TTD-IN-1 5 Publications Verification	Histone Methyltransferase Akt	Cancer
SETDB1-TTD-IN-1 is a *SETDB1* methyltransferase activator and *SETDB1-TTD* competitive inhibitor (K_d of 88 nM), and selectivity for SETDB1-TTD over other tudor and bromodomain proteins. SETDB1-TTD-IN-1 stimulates methyltransferase activity via increased catalytic activity, promotes *Akt1* Lys64 methylation, Akt1 Thr308 phosphorylation and activation. SETDB1-TTD-IN-1 prevents SETDB1-TTD-histone H3 peptide association, induces global gene expression changes, exhibits cellular target engagement, and acts as a tool compound for SETDB1-TTD function exploration. SETDB1-TTD-IN-1 can be used for the research of breast cancer ^[1] .

Perfluorotetradecanoic acid PFTeDA	PPAR Apoptosis PGC-1α AMPK Akt mTOR Reactive Oxygen Species (ROS)	Endocrinology
Perfluorotetradecanoic acid (PFTeDA) is an orally active perfluoroalkyl substance. Perfluorotetradecanoic acid directly binds to the ligand-binding domain of purified hPPARγ, with a K_d value of 157.8 μM. Perfluorotetradecanoic acid significantly reduces the activity of the *SIRT1/PGC1α* and AMPK signaling pathways while stimulating the activity of the *AKT1/mTOR* signaling pathway. Perfluorotetradecanoic acid significantly upregulates the expression of corticosterone biosynthesis genes. Perfluorotetradecanoic acid increases ROS levels and promotes Apoptosis. Perfluorotetradecanoic acid impairs Leydig cell function and male reproductive endocrine function in adult male rats ^[1] .

Sulfabenzamide 1 Publications Verification N-Sulfanilylbenzamide	Bacterial Autophagy MDM-2/p53 Caspase PARP DNA-PK Akt	Infection Cancer
Sulfabenzamide (N-Sulfanilylbenzamide) is a sulfonamide antibacterial agent. Sulfabenzamide exhibit antibacterial activity against Staphylococcus aureus (ATCC 25923) and Escherichia coli (ATCC 8739). Sulfabenzamide can promote autophagic cell autophagy in breast cancer cells through p53/ DRAM pathway. Sulfabenzamide increases caspase-3 activity, deactivates *PARP1* and DNA-PK, downregulates *AKT1* and *AKT2*. Sulfabenzamide can be used for the researches of breast cancer and bacterial infections ^[1] .

Vevorisertib 1 Publications Verification ARQ 751	Akt Ser/Thr Protease	Cancer
Vevorisertib (ARQ 751) is an orally active, potent and selective *pan-AKT* serine/threonine kinase inhibitor against *AKT1* (IC₅₀=0.55 nM), *AKT2* (IC₅₀=0.81 nM), and *AKT3* (IC₅₀=1.31 nM). Vevorisertib, as a single agent or in combination with other anti-cancer agents, can be used for the research of solid tumors with PIK3CA / AKT / PTEN mutations ^[1] .

Akt1/Akt2-IN-1 2 Publications Verification	Akt	Cancer
Akt1/Akt2-IN-1 (Compound 17) is an allosteric inhibitor of *Akt1* (IC₅₀=3.5 nM) and *Akt2* (IC₅₀=42 nM), with potent and balanced activity ^[1].

3CAI 4 Publications Verification	Akt	Cancer
3CAI is a potent and specific *AKT1* and *AKT2* inhibitor.

AKT-IN-6 2 Publications Verification	Akt	Cancer
AKT-IN-6 (Example 13) is a potent Akt inhibitor. AKT-IN-6 inhibits Akt1, Akt2 and Akt3 with IC₅₀s < 500nM, respectively. (patent WO2013056015A1).

Regaloside C	Estrogen Receptor/ERR Toll-like Receptor (TLR) Akt MMP HSP	Inflammation/Immunology
Regaloside C is an anti-inflammatory agent and antioxidant that scavenges ABTS and DPPH free radicals. *Regaloside C targets multiple molecules including TNF-α, MMP-2, ERα, AKT1, TLR4* and HSP90-α. Regaloside C is applicable to research related to inflammatory diseases ^[1] .

Akt1/Akt2-IN-2	Akt Caspase	Cancer
Akt1/Akt2-IN-2 (compound 7) is an allosteric dual *Akt1* and *Akt2* inhibitor (IC₅₀=138 nM and 212 nM, respectively). Akt1/Akt2-IN-2 increases activity of caspase-3, and inhibits viability of a number of tumor cells ^[1].

MS15 TFA	PROTACs Akt	Cancer
MS15 TFA is a potent and selective AKT PROTAC degrader. MS15 TFA inhibits the AKT1, -2, and -3 activities, with IC₅₀ values of 798 nM, 90 nM, and 544 nM, respectively ^[1].

MS170 1 Publications Verification	PROTACs Akt	Cancer
MS170 is a potent and selective PROTAC AKT degrader. MS170 depletes cellular total *AKT* (T-AKT) with the DC₅₀ value of 32 nM. MS170 binds to AKT1, AKT2, and AKT3 with K_ds of 1.3 nM, 77 nM, and 6.5 nM, respectively ^[1].

24-Methylenecycloartanyl ferulate	Akt	Cancer
24-Methylenecycloartanyl ferulate is a γ-oryzanol compound. 24-Methylenecycloartanyl ferulate promotes parvin-beta expression in human breast cancer cells. 24-Methylenecycloartanyl ferulate is a potential ATP-competitive *Akt1* inhibitor (EC₅₀= 33.3μM) ^[1].

DTPD-Q	Akt	Endocrinology
DTPD-Q is an antioxidant and an oxidative derivative of methylbenzenesulfonyl-p-phenylenediamine DTPD. DTPD-Q is a molecule that binds to *AKT1* and *ESR1*, with high binding affinity to core targets associated with male infertility and its subtypes. DTPD-Q can be used in studies related to male infertility ^[1] .

INY-03-041 trihydrochloride 1 Publications Verification	PROTACs Akt	Cancer
INY-03-041 trihydrochloride is a potent, highly selective and PROTAC-based pan-AKT degrader consisting of the ATP-competitive *AKT* inhibitor Ipatasertib (HY-15186) conjugated to Lenalidomide (HY-A0003). INY-03-041 trihydrochloride inhibits *AKT1, AKT2* and *AKT3* with IC₅₀s of 2.0, 6.8 and 3.5 nM, respectively ^[1].

SK1-I 1 Publications Verification BML-258	SphK CaMK	Cancer
SK1-I (BML-258), an analog of sphingosine, is an isozyme-specific competitive *SPHK1* inhibitor with a K_i value of 10 μM ^[1]. SK1-I shows no activity at SPHK1 PKCα, PKCδ, PKA, AKT1, ERK1, EGFR, CDK2, IKKβ or CamK2β. SK1-I enhances autophagy and has antitumor activity .

AKT1-IN-9	Akt	Cancer
AKT1-IN-9 (4) is a selective mutant *AKT1(E17K)* inhibitor, with EC₅₀ values of 9 nM and 995 nM in LAPC4-CR and SkBr3 cells, respectively ^[1].

MS15	PROTACs Akt	Cancer
MS15 is a potent and selective AKT PROTAC degrader. MS15 inhibits the AKT1, -2, and -3 activities, with IC₅₀ values of 798 nM, 90 nM, and 544 nM, respectively ^[1].

Notoginsenoside R4	VEGFR STAT Akt Ras	Others
Notoginsenoside R4 is a ginsenoside that can be isolated from ginseng roots. In the molecular docking results, Notoginsenoside R4 can target STAT3, AKT1, HRAS, VEGFA and CASP3 ^[1] .

AT7867 dihydrochloride 5 Publications Verification	Akt PKA Ribosomal S6 Kinase (RSK)	Cancer
AT7867 dihydrochloride is a potent ATP-competitive inhibitor of *Akt1/Akt2/Akt3* and p70S6K/PKA with IC₅₀s of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively.

Cat. No.	Product Name

HY-L015

PI3K/Akt/mTOR Compound Library

1,049 compounds

The PI3K/Akt/mTOR pathway controls many cellular processes that are important for the formation and progression of cancer, including apoptosis, transcription, translation, metabolism, angiogenesis, and cell cycle progression. Every major node of this signaling network is activated in a wide range of human tumors. Mechanisms for the pathway activation include activation of receptor tyrosine kinases (RTKs) upstream of PI3K, mutation or amplification of PIK3CA encoding p110α catalytic subunit of PI3K, mutation or loss of PTEN tumor suppressor gene, and mutation or amplification of Akt1. Once the pathway is activated, signaling through Akt can stimulate a series of substrates including mTOR which is involved in protein synthesis. Thus, inhibition of this pathway is an attractive concept for cancer prevention and/or therapy. Currently some mTOR inhibitors are approved for several indications, and there are several novel PI3K/Akt/mTOR inhibitors in clinical trials.

MCE owns a unique collection of 1,049 compounds that can be used for PI3K/Akt/mTOR pathway research. PI3K/Akt/mTOR Compound Library also acts as a useful tool for anti-cancer drug discovery.

Cat. No.	Product Name	Target	Research Area

HY-P5910

Azurin p28 peptide	MDM-2/p53 Apoptosis	Cancer
Azurin p28 peptide is a tumor-penetrated antitumor peptide. Azurin p28 peptide redues proteasomal degradation of p53 through formation of a p28: p53 complex. Azurin p28 peptide induces apoptosis or cell cycle arrest. Azurin p28 peptide inhibits p53-positive tumor growths. Azurin p28 peptide shows antiangiogenic effect by inhibiting phosphorylation of VEGFR-2, FAK and Akt .

HY-P5910A

Azurin p28 peptide TFA	MDM-2/p53 Apoptosis	Cancer
Azurin p28 peptide TFA is a tumor-penetrated antitumor peptide. Azurin p28 peptide TFA redues proteasomal degradation of p53 through formation of a p28: p53 complex. Azurin p28 peptide TFA induces apoptosis or cell cycle arrest. Azurin p28 peptide TFA inhibits p53-positive tumor growths. Azurin p28 peptide TFA shows antiangiogenic effect by inhibiting phosphorylation of VEGFR-2, FAK and Akt .

HY-P10064

Akt Substrate	Peptides	Others
Akt Substrate (Akt/SKG substrate) is a 7 amino acid synthetic peptide suitable as a substrate for *Akt* .

Recombinant Proteins Recommended:

AKT Serine/Threonine Kinase 1 (AKT1)

Species:	Human (3)
Tag:	His (1) GST (3)
Source:	sf9 insect cells (1) Sf9 insect cells (2)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P704088

	AKT1 Protein, Human (Active, S473D, sf9, His, GST) RAC-alpha serine/threonine-protein kinase; PKB; RAC-PK-alpha; AKT1; RAC	Human	Sf9 insect cells
	The AKT1 protein is part of the AKT kinase family and is critical for metabolism, proliferation, survival, growth, and angiogenesis. It phosphorylates more than 100 substrates, coordinates insulin-induced SLC2A4/GLUT4 translocation, affects glucose uptake, and controls glycogen storage through inhibition of GSK3A/B. AKT1 Protein, Human (S473D, sf9, His, GST) is the recombinant human-derived AKT1 protein, expressed by Sf9 insect cells, with N-His and N-GST labeled tag.

HY-P702631

	AKT1 Protein, Human (Active, sf9, GST) 1 Publications Verification AKT1; v-AKT murine thymoma viral oncogene homolog 1; RAC-alpha serine/threonine-protein kinase; AKT; PKB; PRKBA; RAC; PKB alpha; RAC-PK-alpha; proto-oncogene c-AKT; protein kinase B alpha; rac protein kinase alpha; PKB-ALPHA; RAC-ALPHA; MGC99656	Human	Sf9 insect cells
	The AKT1 protein is part of the AKT kinase family and is critical for metabolism, proliferation, survival, growth, and angiogenesis. It phosphorylates more than 100 substrates, coordinates insulin-induced SLC2A4/GLUT4 translocation, affects glucose uptake, and controls glycogen storage through inhibition of GSK3A/B. AKT1 Protein, Human (Active, sf9, GST) is the recombinant human-derived AKT1, expressed by Sf9 insect cells, with GST labeled tag. The total length of AKT1 Protein, Human (Active, sf9, GST) is 480 a.a..

HY-P705727

	AKT1 Protein, Human (Active, E17K, sf9, GST) AKT1; v-AKT murine thymoma viral oncogene homolog 1; RAC-alpha serine/threonine-protein kinase; AKT; PKB; PRKBA; RAC; PKB alpha; RAC-PK-alpha; proto-oncogene c-AKT; protein kinase B alpha; rac protein kinase alpha; PKB-ALPHA; RAC-ALPHA; MGC99656	Human	sf9 insect cells

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-B0960S

Sulfabenzamide-d4

Sulfabenzamide (N-Sulfanilylbenzamide)-d₄ is the deuterium labeled Sulfabenzamide (HY-B0960). Sulfabenzamide is a sulfonamide antibacterial agent. Sulfabenzamide exhibit antibacterial activity against Staphylococcus aureus (ATCC 25923) and Escherichia coli (ATCC 8739). Sulfabenzamide can promote autophagic cell autophagy in breast cancer cells through p53/ DRAM pathway. Sulfabenzamide increases caspase-3 activity, deactivates PARP1 and DNA-PK, downregulates AKT1 and AKT2. Sulfabenzamide can be used for the researches of breast cancer and bacterial infections ^[1] .

Host:	Mouse (9) Rabbit (17)
Reactivity:	Transfected (1) Human (25) Bovine (1) Rat (21) Mouse (20) Monkey (4) Chicken (1) Dog (1) Hamster (2) Pig (1)
Application:	IHC-P (15) ICC/IF (16) IF-Tissue (1) IP (12) WB (25) IHC-F (3) FC (8) ELISA (9)
Isotype:	IgG3,IgG/Kappa (1) IgG (16) IgG1 (4) IgG/Kappa (1) IgG2b (1)
Conjugation:	Non-conjugated (26)
Clonality:	Polyclonal (1) Monoclonal (16) Recombinant (6)
Modification:	Phosphorylated (5) Unmodified (12)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P80008

	AKT1 Antibody (YA634) AKT 1; AKT; AKT1; AKT1_HUMAN ; MGC99656; PKB; PKB-ALPHA; PRKBA; Protein Kinase B Alpha ; Proto-oncogene c-AKT; RAC Alpha;	IHC-P, IHC-F, ICC/IF, IP, FC	Human, Mouse
	AKT1 Antibody (YA634) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to AKT1.

HY-P85759

	AKT Antibody (YA5451) AKT1	WB, IP, ICC/IF, ELISA	Human, Mouse, Rat
	AKT Antibody (YA5451) is a Mouse-derived and non-conjugated IgG3 monoclonal antibody, targeting to AKT.

HY-P86067

	*Phospho-AKT(S473) Antibody (YA5759)* AKT1	WB, IHC-P, ICC/IF	Human
	Phospho-AKT(S473) Antibody (YA5759) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to Phospho-AKT(S473).

HY-P85561

	AKT1 Antibody (YA5253) AKT 1; AKT; AKT1; AKT1_HUMAN; C AKT; MGC99656; PKB; PKB-ALPHA; PRKBA; Protein Kinase B Alpha; Protein kinase B; Proto-oncogene c-AKT; RAC Alpha; RAC; RAC PK Alpha; RAC Serine/Threonine Protein Kinase; RAC-alpha serine/threonine-protein kinase; RAC-PK-alpha; vAKT Murine Thymoma Viral Oncogene Homolog 1	WB	Mouse, Transfected
	AKT1 Antibody (YA5253) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to AKT1.

HY-P80276

	*Phospho-AKT1(Ser473) Antibody (YA227)* 4 Publications Verification AKT 1 antibody; AKT antibody; AKT1 antibody; AKT1_HUMAN antibody; MGC99656 antibody; PKB antibody; PKB-ALPHA antibody; PRKBA antibody; Protein Kinase B Alpha antibody; Protein kinase B antibody; Proto-oncogene c-AKT antibody; RAC Alpha antibody; RAC antibody; RAC-alpha serine/threonine-protein kinase antibody; RAC-PK-alpha antibody;	WB, ICC/IF, IHC-P	Human, Mouse, Rat, Dog
	Phospho-AKT1(Ser473) Antibody (YA227) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-AKT1(Ser473).

HY-P85416

	AKT1 Antibody (YA5108) AKT1; PKB; RAC; RAC-alpha serine/threonine-protein kinase; Protein kinase B; PKB; Protein kinase B alpha; PKB alpha; Proto-oncogene c-AKT; RAC-PK-alpha	WB	Human, Mouse, Rat, Bovine, Chicken, Pig
	AKT1 Antibody (YA5108) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to AKT1.

HY-P80007

	AKT1 Antibody (YA834) 1 Publications Verification	WB, IHC-P, ICC/IF	Human
	AKT1 Antibody (YA834) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to AKT1.

HY-P80009

	AKT1/2/3 Antibody (YA633) 1 Publications Verification	WB, ICC/IF, IHC-P, IP, FC	Human, Mouse
	AKT1/2/3 Antibody (YA633) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to AKT1/2/3.

HY-P84253

	AKT1 Antibody (YA3950) AKT; PKB; RAC; CWS6; PRKBA; PKB-ALPHA; RAC-ALPHA	WB, ICC/IF, FC, ELISA	Human, Mouse, Monkey, Rat
	AKT1 Antibody (YA3950) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to AKT1.

HY-P84254

	AKT1 Antibody (YA3951) AKT; PKB; RAC; CWS6; PRKBA; PKB-ALPHA; RAC-ALPHA	WB, IHC-P, FC, ELISA	Human, Rat, Monkey
	AKT1 Antibody (YA3951) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to AKT1.

HY-P83434

	PRAS40 Antibody (YA3179) AKT1S1; PRAS40; Proline-rich AKT1 substrate 1; 40 kDa proline-rich AKT substrate	WB, IP	Human, Rat
	PRAS40 Antibody (YA3179) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PRAS40.

HY-P86433

	PRAS40 Antibody (YA6125) AKT1S1; PRAS40; Proline-rich AKT1 substrate 1; 40 kDa proline-rich AKT substrate	WB, ICC/IF, IP, ELISA	Human, Mouse, Rat
	PRAS40 Antibody (YA6125) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PRAS40.

HY-P84253A

	AKT1 Antibody (YA3950)(PBS only) AKT; PKB; RAC; CWS6; PRKBA; PKB-ALPHA; RAC-ALPHA	WB, ICC/IF, FC, ELISA	Human, Mouse, Monkey, Rat
	AKT1 Antibody (YA3950) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to AKT1.

HY-P84254A

	AKT1 Antibody (YA3951)(PBS only) AKT; PKB; RAC; CWS6; PRKBA; PKB-ALPHA; RAC-ALPHA	WB, IHC-P, FC, ELISA	Human, Rat, Monkey
	AKT1 Antibody (YA3951) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to AKT1.

HY-P83434A

	PRAS40 Antibody (YA3179)(PBS only) AKT1S1; PRAS40; Proline-rich AKT1 substrate 1; 40 kDa proline-rich AKT substrate	WB, IP	Human, Rat
	PRAS40 Antibody (YA3179) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PRAS40.

HY-P86153

	Phospho-PRAS40(Thr246) Antibody (YA5845) AKT1S1; PRAS40; Proline-rich AKT1 substrate 1; 40 kDa proline-rich AKT substrate	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	Phospho-PRAS40(Thr246) Antibody (YA5845) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-PRAS40(Thr246).

HY-P80788

	*Phospho-AKT1* (Ser473) Antibody (YA228)** 4 Publications Verification AKT1; PKB; RAC; RAC-alpha serine/threonine-protein kinase; Protein kinase B; PKB; Protein kinase B alpha; PKB alpha; Proto-oncogene c-AKT; RAC-PK-alpha	WB	Human, Mouse, Rat
	Phospho-AKT1 (Ser473) Antibody (YA228) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-AKT1 (Ser473).

HY-P810599

	*Phospho-AKT1* (Thr450) Antibody (YA9862)** AKT1; PKB; RAC; RAC-alpha serine/threonine-protein kinase; Protein kinase B; PKB; Protein kinase B alpha; PKB alpha; Proto-oncogene c-AKT; RAC-PK-alpha	WB, IHC-P, IP, ICC/IF, FC	Human, Mouse, Rat
	Phospho-AKT1 (Thr450) Antibody (YA9862) is a Rabbit-derived and non-conjugated IgG Recombinant, Monoclonal antibody, targeting to Phospho-AKT1 (Thr450).

HY-P810598

	*Phospho-AKT1* (Ser129) Antibody (YA9861)** AKT1; PKB; RAC; RAC-alpha serine/threonine-protein kinase; Protein kinase B; PKB; Protein kinase B alpha; PKB alpha; Proto-oncogene c-AKT; RAC-PK-alpha	WB	Human, Mouse, Rat
	Phospho-AKT1 (Ser129) Antibody (YA9861) is a Rabbit-derived and non-conjugated IgG Recombinant, Monoclonal antibody, targeting to Phospho-AKT1 (Ser129).

HY-P810600

	*Phospho-AKT1* (Ser124) Antibody (YA9863)** AKT1; PKB; RAC; RAC-alpha serine/threonine-protein kinase; Protein kinase B; PKB; Protein kinase B alpha; PKB alpha; Proto-oncogene c-AKT; RAC-PK-alpha	WB, ICC/IF, IF-Tissue, IHC-P, IP	Human, Mouse, Rat
	Phospho-AKT1 (Ser124) Antibody (YA9863) is a Rabbit-derived and non-conjugated IgG Recombinant, Monoclonal antibody, targeting to Phospho-AKT1 (Ser124).

HY-P80788A

	*Phospho-AKT1* (Ser473) Antibody (YA228)(PBS only)** AKT1; PKB; RAC; RAC-alpha serine/threonine-protein kinase; Protein kinase B; PKB; Protein kinase B alpha; PKB alpha; Proto-oncogene c-AKT; RAC-PK-alpha	WB	Human, Mouse, Rat
	Phospho-AKT1 (Ser473) Antibody (YA228) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-AKT1 (Ser473).

HY-P80789

	*Phospho-AKT* (Thr308) Antibody** 2 Publications Verification AKT1; PKB; RAC; RAC-alpha serine/threonine-protein kinase; Protein kinase B; PKB; Protein kinase B alpha; PKB alpha; Proto-oncogene c-AKT; RAC-PK-alpha	WB, IHC-P, ICC/IF, ELISA	Human, Mouse, Rat
	Phospho-AKT (Thr308) Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to Phospho-AKT (Thr308).

HY-P810597

	*Phospho-AKT* (Ser473) Antibody (YA9860)** AKT1; PKB; RAC; RAC-alpha serine/threonine-protein kinase; Protein kinase B; PKB; Protein kinase B alpha; PKB alpha; Proto-oncogene c-AKT; RAC-PK-alpha	WB, IHC-P, FC	Human, Mouse, Rat
	Phospho-AKT (Ser473) Antibody (YA9860) is a Rabbit-derived and non-conjugated IgG Recombinant, Monoclonal antibody, targeting to Phospho-AKT (Ser473).

HY-P80535

	AKT1+AKT2+AKT3 Antibody (YA635) 5 Publications Verification AKT1,AKT2,AKT3	WB, IHC-F, IHC-P, ICC/IF, IP	Human, Mouse, Rat, Hamster
	AKT1+AKT2+AKT3 Antibody (YA635) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to AKT1+AKT2+AKT3.

HY-P80535A

	AKT1+AKT2+AKT3 Antibody (YA635)(PBS only) AKT1,AKT2,AKT3	WB, IHC-F, IHC-P, ICC/IF, IP	Human, Mouse, Rat, Hamster
	AKT1+AKT2+AKT3 Antibody (YA635) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to AKT1+AKT2+AKT3.

HY-P86312

	AKT1/2/3 Antibody (YA6004) 2 Publications Verification	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	AKT1/2/3 Antibody (YA6004) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to AKT.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-130985

9-Decyn-1-ol		Alkynes PROTAC Synthesis
9-Decyn-1-ol is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs. 9-Decyn-1-ol can be used to conjugate GDC-0068 with Lenalidomide to generate INY-03-041. INY-03-041 is a potent, highly selective and PROTAC-based pan-Akt degrader. INY-03-041 inhibits Akt1, Akt2 and Akt3 with IC₅₀s of 2.0 nM, 6.8 nM and 3.5 nM, respectively ^[1]. 9-Decyn-1-ol is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Cat. No.	Product Name		Classification

HY-RS00542

AKT1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
AKT1 Human Pre-designed siRNA Set A contains three designed siRNAs for AKT1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS00544

Akt1 Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Akt1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Akt1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS00543

Akt1 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Akt1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Akt1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-177616

Archexin RX-0201		Antisense Oligonucleotides
Archexin is an antisense oligonucleotide (ASO) against Akt1. It is used for the study of metastatic renal cancer.

HY-177616A

Archexin sodium RX-0201 sodium		Antisense Oligonucleotides
Archexin sodium is an antisense oligonucleotide (ASO) against Akt1. It is used for the study of metastatic renal cancer.

HY-RS00545

AKT1S1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
AKT1S1 Human Pre-designed siRNA Set A contains three designed siRNAs for AKT1S1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks